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Background/aim: Coronavirus disease 2019 (COVID-19) has a wide clinical spectrum from asymptomatic to mild, moderate, and
severe cases. There are still many unknowns about the role of immunoregulatory mechanisms in COVID-19. We aimed to study
regulatory T cells (Tregs) and B cell subsets and evaluate their correlations with severity of COVID-19.
Materials and methods: In total, 50 patients with COVID-19 confirmed by PCR (mean age = 49.9 ± 12.8 years) and 40 healthy control
(mean age = 47.9 ± 14.7 years) were included in this study. The patients were classified as 14 mild (median age = 35.5 [24–73] years), 22
moderate (median age = 51.5 [28–67] years) and 14 severe (median age = 55.5 [42–67] years). Within 24 h of admission, flow cytometry
was used to assess the lymphocyte subsets, Tregs and Bregs without receiving any relevant medication.
Results: In all patients with COVID-19, the proportion of CD3+CD8+ T cells was reduced (p = 0.004) and the CD8+ Tregs were increased
compared with control (p = 0.001). While the levels of regulatory B cells, plasmablasts, and mature naive B cells were found to be
significantly high, primarily memory B-cell levels were low in all patients compared with controls (p < 0.05). Total CD3+ T cells were
negatively correlated with the length of stay in the hospital (r = –0.286, p = 0.044).
Conclusion: The changes in T and B cell subsets may show the dysregulation in the immunity of patients with COVID-19. In this
context, the association between CD8+ Tregs and COVID-19 severity may help clinicians to predict severe and fatal COVID-19 in
hospitalized patients.
Key words: SARS-CoV-2, COVID-19, regulatory B cells, regulatory T cells

1. Introduction
The World Health Organization classified the coronavirus
disease 2019 (COVID-19) as an outbreak on January 30,
2020 and as a pandemic on March 11, 2020 due to the
spread of COVID-19 cases to 220 countries outside of
China—the country where the outbreak began [1]. In our
country, the first case with COVID-19 was reported on
March 11, 2020 after neighboring countries in Europe and
Iran [2].
The coronaviruses (CoV) are a large family of viruses
that are common worldwide, ranging in severity from the
common cold, which can cause self-limiting mild infection
manifestations, to more serious infections, such as Middle
East respiratory syndrome (MERS) and severe acute
respiratory syndrome (SARS) [3]. The clinical findings

of the SARS-CoV-2 infection are in the broad spectrum,
starting from mild forms, such as asymptomatic disease
and mild upper respiratory tract infection, accompanied by
respiratory failure and severe viral pneumonia resulting in
death [4,5]. It is known that age, sex, and the presence of
chronic diseases (such as cardiovascular disease, diabetes,
chronic obstructive pulmonary disease, etc.) affect the
course of the disease in patients infected with SARS-CoV-2
[6,7].
CD3+ T cells, CD3+CD4+ T cells, and CD3+CD8+ T
cells play a central role in antiviral responses. CD3+CD4+
T cells promote the production of virus‐specific antibodies
by activating T‐dependent CD19+ B cells. CD3+CD8+
T cells are cytotoxic and can kill viral infected cells.
Changes in T lymphocyte subsets of the patients with
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COVID-19 reported in especially severe cases [7,8].
Lymphopenia commonly correlates with the severity
of the disease, especially within the CD8 subset [9].
Predictive immunological data about severe COVID-19
infection is needed to triage these patients. Understanding
the disease’s immunological basics may help prevent the
progression to severe disease, including cytokine storm
and acute respiratory distress syndrome.
During viral infections, host factors trigger an immune
response against the virus. However, it should be noted
that an uncontrolled immune response may lead to
damage of the respiratory tract and other tissues in SARSCoV infections [8]. Tregs have been shown to limit the
extent of virus-induced immunopathology in several virus
infections [10,11]. Previous studies have demonstrated that
Bregs contribute to immune dysfunction associated with
HIV infection via T-cell impairment [12–14]. The effects
of B-cell-mediated humoral immunity on the clearance
of viral infection are limited, and the role of Bregs is still
unclear [15]. In this study, we focused on regulatory T
cells (Tregs) and regulatory B cells (Bregs) in patients with
COVID-19, and we evaluate their relationship with the
clinical findings.
2. Materials and methods
2.1. Study design and participants
Symptomatic patients with positive SARS-CoV-2 PCR
admitted to the Department of Infectious and Chest
Diseases from May to June 2020 were recruited in
this prospective, single-centered, observational, casecontrolled study. Written informed consent was obtained
from all patients. Samples were obtained at the time of
first admission and viral phase before starting treatment.
Peripheral venous blood samples were storage at room
temperature before staining. Lymphocyte subsets, Tregs
and Bregs, were analyzed by flow cytometry within 24 h.
The patients’ demographic data, clinical history, laboratory,
radiological findings, and their treatments were obtained
from medical records upon admission.
Patients who were under the influence of alcohol or
drugs that could cause lymphopenia during treatment, as
well as those with chronic renal disease, Cushing syndrome,
and/or active cancer, were excluded. The control group
consisted of an age and sex-matched healthy adults without
the disease. Individuals in the control group with any of
the following chronic diseases were also excluded from the
study: primary immunodeficiency, chronic kidney or liver
disease, active infection, or malignancy. None of them was
vaccinated for COVID-19 in the time of study.
COVID-19 patients were divided into three subgroups:
mild, moderate, and severe. Those who had mild
symptoms or radiologically absent pneumonic findings,
were considered as “mild”. Those with fever or respiratory

symptoms and radiological signs of pneumonia were
considered to be “moderate”. Patients with the following
criteria were considered as “severe”: 1) respiratory rate
of ≥ 30 breaths/min and dyspnea; 2) SpO2 ≤ 93% at
rest; 3) PaO2/ iO2 ≤ 300 mmHg; 4) bilateral multilobar,
ground glass, and infiltration in radiological imaging
(thorax computed tomography); and 5) respiratory failure
requiring noninvasive mechanical ventilation [16].
2.2. Flow cytometry analysis
For T-cell subsets and Treg cells, peripheral blood
mononuclear cells (PBMCs) were isolated from 2 mL
of blood collected in vacutainer glass tubes containing
ethylenediaminetetraacetic acid (EDTA). PBMCs were
isolated using lymphopure (Biolegend, San Diego, CA).
PBMCs were thawed and stained with CD3 (Peridinin
chlorophyll protein-Cyanine5.5 (PerCP-Cy5.5), Biolegend,
San Diego, CA), CD4 (Allophycocyanin (APC), Becton
Dickinson (BD) Bioscience, CA, USA), CD8 (Alexa flour
700, BD Bioscience, CA, USA), CD25 (Phycoerythrin
(PE), BD Bioscience, CA, USA), and CD45RA (PE-Cy7,
Biolegend, San Diego, CA) extracellularly. Cells were fixed
using Foxp3 fixation buffer, stained in permeabilization
buffer (BD Bioscience, CA, USA), and labeled with Foxp3
(Fluorescein-5-isothiocyanate (FITC), BD Bioscience,
CA, USA) intracellularly. The proportions of CD3+,
CD3+CD4+, CD3+CD8+, CD3+CD4+CD25+Foxp3+ (CD4+
Tregs), and CD3+CD8+CD25+Foxp3+ (CD8+ Tregs)
were studied in patients and controls (Figure 1A). Also,
human Tregs can be divided into three distinct subsets
based on Foxp3 level and CD45RA expression [17]:
CD3+CD4+CD45RA+Foxp3low (resting Tregs: rTregs),
CD3+CD4+CD45RA-Foxp3high (activated Tregs: aTregs),
and CD3+CD4+CD45RA-Foxp3low (nonsuppressive Tregs)
(Figure 1B).
For the B-cell subsets, peripheral blood samples
were collected into vacutainer glass tubes containing
EDTA. Blood (100 µL) was transferred into a 12 × 75
mm test tube, and cells were stained with combinations
of CD19 (FITC), CD24 (PE), and CD38 (APC) mAbs
(all antibodies were obtained from Biolegend, San Diego,
CA). The samples were incubated in the dark at room
temperature for 20 min. The whole blood lysis method
was used. Human B-cell subsets can be divided into five
distinct subsets based on CD24 and CD38 expression [18]:
CD19+CD38highCD24high (Bregs), CD19+CD38highCD24(plasmablasts), CD19+CD38intCD24int (mature naïve B
cells, int: intermediate), CD19+CD38-CD24+ (primarily
memory B cells), and CD19+CD38-CD24- (new memory
B cells) (Figure 2).
Samples were analyzed by dot plots using the
Fluorescence-Activated Cell Sorting (FACS) Diva software
package (BD Biosciences, CA, USA) with BD FACS ARIA
III (BD Biosciences, CA, USA).
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Figure 1. Flow cytometry gating strategy for identification of
Treg cells. A. CD4+ Treg (CD3+CD4+CD25+Foxp3+) cells and
CD8+ Treg (CD3+CD8+CD25+Foxp3+) cells were determined
based on the expression of Foxp3+ and CD25+ in peripheral
blood. B. Three subsets of CD4+ T cells are defined by the
expression of CD45RA and Foxp3. I: Resting Treg=rTreg
(CD3+CD4+CD45RA+Foxp3low), II: Activated Treg=aTreg
(CD3+CD4+CD45RA-Foxp3high), III: Nonsuppressive Treg=nonTreg (CD3+CD4+CD45RA-Foxp3low).

2.3. Statistical analysis
All analysis was performed using a statistical software
package (SPSS for Windows, version 21.0, IBM
Corporation, Armonk, NY, USA). Numerical data were
expressed as mean ± standard deviation (SD) or median
(range: minimum–maximum), as appropriate. Categorical
variables were described as count (n) and percentages
(%). To assess the normality of the data, Shapiro–Wilk’s
normality test and Q-Q plots were used. And also, Levene’s
test were used to check the homogeneity of the variances.
A Welch F test was run to compare the patient ages of
the study groups. In addition to, Yates continuity correction
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chi-square and Fisher’s exact test were conducted to
examine the sex and comorbidity distribution between
the study groups. Also, we performed the Welch F test
and Kruskal–Wallis test to compare whether there was a
statistically significant difference between the study groups
regarding to laboratory and flow cytometry findings. When
the variables found to be significant with Welch F and
Kruskal–Wallis test, we carried out multiple comparisons.
The Games-Howell test and Dunn test with Bonferroni
correction were applied for pairwise comparisons. Due
to the albumin and total bilirubin values were observed
only moderate and severe patient groups, we compared
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these values independent samples t-test. A independent
samples t-test and Mann–Whitney U test were conducted
to examine the difference between patients and healthy
controls according to flow cytometry findings.
Correlations were analyzed with the Spearman test.
Statistical significance was considered at p-values less than
0.05.
An a priori power analysis was conducted using
“pwr” packages in R 3.6.0 (www.r-project.org) to test
the difference between two independent groups (COVID
patients and controls) using a two-tailed test, a large effect
size (d =0.80), and an alpha of 0.05. Result showed that a
total sample of 34 participants with two equal sized groups
of n = 68 was required to achieve a power of 0.90. Our
study included 50 patients and 40 controls.
3. Results
3.1. Demographic characteristics
In this study, 50 patients confirmed to have COVID-19 by
PCR testing and 40 healthy controls were included. The
patient group consisted of 27 females and 23 males. Their
ages ranged from 24 to 73 years, with a mean age of 49.9
± 12.8 years; this age did not differ significantly from the
age of the control group (mean age 47.9 ± 14.7 years, range
25 to 82 years) (p = 0.482). Also, the sex distribution of the
study groups was similar (15 females and 25 males) (p =
0.178).
The COVID-19 patients were divided into three
subgroups: mild, moderate, and severe. There were 14

mild cases with a median age of 35.5 years (range, 24 to
73 years), 22 moderate cases with a median age of 51.5
years (range, 28 to 67 years), and 14 severe cases with a
median age of 55.5 years (range, 42 to 67 years). There was
no significant difference in age among groups of patients
with COVID-19 (p = 0.085) (Table 1).
3.2. Clinical and laboratory findings
The most common symptoms were cough (66.0%),
fever (36.0%), shortness of breath (34.0%), and fatigue
(26.0%). Chills and shivering, sore throat, loss of taste
and smell were recorded as the other symptoms. Of the
50 COVID-19 patients, 11 (22.0%) had diabetes, 9 (18.0%)
had hypertension, and 4 (8.0%) had asthma. Although the
number of patients with hypertension and diabetes in the
severe group was higher than in the mild and moderate
groups, the difference was not statistically significant
(Table 1).
The level of oxygen saturation was below 92.0% in
the severe group, and ARDS developed in 7 (50.0%) of
them; 5 of these 7 patients received mechanical ventilation
treatment in the intensive care unit. The other seven
patients improved with high-flow oxygen therapy. In
addition to other treatments, six patients followed in the
intensive care unit received anticytokine therapy (n = 3)
and convalescent plasma therapy (n = 3). Three patients
treated with invasive mechanical ventilation died of
respiratory failure on the 13th, 16th, and 18th days of
follow-up; two of these patients had received tocilizumab
treatment.

Figure 2. Flow cytometry gating strategy for identification of B cell subsets. The expression of CD24 and CD38 defines
five subsets of CD19+ B cells. B regulatory cell (Breg): CD19+CD38highCD24high, Plazmablast: CD19+CD38highCD24-,
Mature Naïve B cell: CD19+CD38intCD24int, Primarily Memory B cell: CD19+CD38-CD24+, New memory B
cell: CD19+CD38-CD24-.
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Table 1. Demographical and clinical characteristics of the COVID-19 patients.

All patients
(n = 50)

Study groups
Mild
(n = 14)

Moderate
(n = 22)

Severe
(n = 14)

p-value

Demographic
Age, years

49.9 ± 12.8

35.5 (24–73)

51.5 (28–67)

55.5 (42–67)

0.0851

Sex (M), n (%)

23 (46.0%)

7 (50.0%)

8 (36.4%)

8 (57.1%)

0.4472

Hypertension

9 (18.0%)

1 (7.1%)

4 (18.2%)

4 (28.6%)

0.4803

Diabetes

11 (22.0%)

1 (7.1%)

3 (13.6%)

7 (50.0%)

0.0493

Asthma

4 (16.0%)

0 (0.0%)

2 (9.1%)

2 (14.3%)

0.5483

Comorbidities, n (%)

Data were presented as mean ± standard deviation or median (min-max), as appropriate.
1
Kruskal–Wallis test.
2
Yates continuity correction chi-square test.
3
Fisher-Freeman-Halton chi-square test.

There was a significant difference between study
groups according to neutrophil, lymphocyte, NLR,
prothrombin
time,
prothrombin-INR,
D-dimer,
fibrinogen, AST, creatinine phosphokinase, LDH, CRP,
ferritin, procalcitonin, troponin I (Table 2). The multiple
comparison tests were indicted that the neutrophile counts
was higher in severe groups compared to the mild group.
The levels of D-dimer, CRP, ferritin, lactate dehydrogenase,
troponin I, AST, procalcitonin, and prothrombin time
were markedly higher in the severe cases than in the
moderate and mild cases. The creatinine phosphokinase,
prothrombin-INR and NLR levels of the severe cases were
higher than in the moderate cases. The fibrinogen levels of
the mild cases were lower than the moderate and severe
cases (Table 2).
3.3. Radiographic characteristics
Of the mild patients, 14 had no lesions compatible
with pneumonia as determined by chest tomography.
Unilateral/bilateral pneumonia was detected in 22 patients
with COVID-19 of moderate severity. Of the severe cases,
14 had bilateral diffuse ground-glass/consolidation.
Typical lesions of the moderate cases were unilateral/
bilateral involvement in the form of subpleural ground
glass. In severe cases, bilateral multilobar, subpleural, and
multifocal localized areas of the ground glass accompanied
by interlobular septal thickening showed progression to
diffuse ground glass and consolidation areas in both lungs
in a short time.
3.4. T-cell subsets and regulatory T cells
Lymphopenia (≤1500/mm3) was found in 34/50
(68.0%) patients. According to subgroups, lymphopenia
was detected in 71.4% of mild cases (10/14), 50.0% of
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moderate cases (11/22), and 92.9% of severe cases (13/14).
The median value of lymphocyte count in severe cases was
lower than moderate cases (1.0 ± 0.3 vs. 1.5 ± 0.6, GamesHowell p = 0.004) (Table 2).
The percentage of CD3+CD8+ T cells in all patients
(21.3 ± 7.2) was lower than controls (26.3 ± 9.2). This
difference was statistically significant (Student’s t p =
0.004) (Figure 3A). However, there was no statistically
significant difference among the groups with COVID-19
in the percentage of total CD3+CD8+ T cells (p = 0.426).
No statistically significant difference was found between
all patients and controls regarding in CD4/CD8 ratio and
the percentage of total CD3+ T cells and CD3+CD4+ T cells.
There was no statistically significant difference among the
groups with COVID-19 in the percentage of total CD3+ T
cells, CD3+CD4+ T cells and CD4/CD8 ratio (all p > 0.05)
(Table 3).
We illustrated naturally occurring Treg cells (the
frequency of CD25+Foxp3+ Tregs in the total CD3+CD4+
T cells) in COVID-19 patients and controls in Figure 1A.
No statistically significant difference was found between
all patients and controls regarding the frequency of Tregs
(Mann–Whitney U p = 0.202).
To determine the frequency of Treg subsets, we could
separate three subpopulations’ natural Tregs based on
CD45RA and Foxp3 expression in the total CD3+CD4+ T
cells: CD3+CD4+CD45RA+Foxp3low (resting Tregs: rTregs),
CD3+CD4+CD45RA-Foxp3high (Activated Tregs: aTregs),
and
CD3+CD4+CD45RA-Foxp3low
(nonsuppressive
Tregs) (Figure 1B). The median values of percentage
of nonsuppressive Tregs in controls was lower than all
patients (3.6 [range, 1.1–11.2] vs. 5 [range, 2.3–13.6],
Mann–Whitney U p = 0.020). There was no statistically
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significant difference among the groups with COVID-19
in other subsets of CD4+ Tregs (all p > 0.05) (Table 3).
The median value of percentage of CD8+ Tregs
(CD3+CD8+CD25+Foxp3+) among all patients with
COVID-19 were higher than controls (0.4 [range, 0–4.2]
vs. 0.3 [range, 0–1.5], Mann–Whitney U p = 0.001) (Figure
3B). The percentage of CD8+ Tregs of the severe cases (0.9
[range, 0.2–4.2]) was higher than of the mild (0.3 [range,
0–1.4], Bonferroni-Dunn test p = 0.006) and moderate
cases (0.4 [range, 0.2–2.2], Bonferroni-Dunn test p =
0.030) (Figure 3C) (Table 3).
3.5. B-cell subsets
Five distinct B-cell populations were determined in the
peripheral blood lymphocytes: CD19+CD38highCD24high
(Bregs),
CD19+CD38highCD24(plasmablasts),
+
int
CD19 CD38 CD24int (mature naïve B cells), CD19+CD38CD24+ (primarily memory B cells), and CD19+CD38CD24- (new memory B cells) (Figure 2). The percentage
of Bregs (3.6 ± 2.2 vs. 5.2 ± 2.8, Student’s t p = 0.005)
plasmablasts (0.3 [range, 0.1–8.4] vs. 2.7 [range, 0–10.4],
Mann–Whitney U p = 0.001) and mature naive B cells
(48.6 [range, 14.7–82.8] vs. 54.6 [range, 19.9–71.7], Mann–
Whitney U p = 0.028) were found to be increased in all
patients compared with controls (Figures 4A and 4B).
The percentage of primarily memory B cells were found
to be decreased in all patients compared with controls
(21.5.6 [range, 8.2–55.8] vs. 34.8 [range, 6.3–73.2],
Mann–Whitney U p = 0.001) (Figure 4B). No statistically
significant difference was found between all patients
and controls regarding the frequency of new memory B
cells (Mann–Whitney U p = 0.247) (Figure 4A). In the
analysis of subgroups, there was no statistically significant
difference among the groups with COVID-19 in all B-cell
subsets (all p > 0.05) (Table 3).
3.6. Correlation of the T-cell subsets, Tregs, and Bregs
between inflammatory markers
Neutrophil counts were positively correlated with
CD4+ Tregs (Pearson’s r = 0.289, p = 0.042), CD8+ Tregs

(Spearman’s rho = 0.436, p = 0.002), nonsuppressive
Tregs (Spearman’s rho = 0.341, p = 0.015), CD19+ B cells
(Pearson’s r = 0.492, p < 0.001), primarily memory B cells
(Spearman’s rho = 0.304, p = 0.032), and were negatively
correlated with Bregs (Pearson’s r = –0.475, p < 0.001).
Lymphocyte counts were positively correlated with
CD3+CD8+ T cells (Pearson’s r = 0.355, p = 0.011) and were
negatively correlated with CD4/CD8 ratio (Spearman’s rho
= –0.285, p = 0.044).
NLR values were positively correlated with CD8+ Tregs
(Spearman’s rho = 0.367, p = 0.009) and were negatively
correlated with Total CD3+ T cells (Spearman’s rho =
–0.302, p = 0.032), CD3+CD8+ T cells (Spearman’s rho =
–0.285, p = 0.045), Bregs (Spearman’s rho = –0.357, p =
0.011) and plasmablasts (Spearman’s rho = –0.318, p =
0.024).
D-dimer values were positively correlated with
CD4+ Tregs (Pearson’s r = 0.330, p = 0.019), CD8+ Tregs
(Spearman’s rho = 0.549, p < 0.001) and nonsuppressive
Tregs (Spearman’s rho = 0.453, p = 0.001).
Fibrinogen values were positively correlated with
nonsuppressive Tregs (Spearman’s rho = 0.508, p = 0.001)
and were negatively correlated with plasmablasts (Pearson’s
r = –0.325, p = 0.049).
CRP values were positively correlated with CD8+ Tregs
(Spearman’s rho = 0.348, p = 0.013) and nonsuppressive
Tregs (Spearman’s rho = 0.366, p = 0.009) and were
negatively correlated with Bregs (Spearman’s rho = –0.434,
p = 0.002).
Ferritin values were positively correlated with CD8+
Tregs (Spearman’s rho = 0.290, p = 0.041) and primarily
memory B cells (Spearman’s rho = 0.313, p = 0.027),
and were negatively correlated with CD3+CD4+ T cells
(Spearman’s rho = –0.295, p = 0.038), CD4/CD8 ratio
(Spearman’s rho = –0.330, p = 0.019) and Bregs (Spearman’s
rho = –0.394, p = 0.005).
Serum albumin levels were positively correlated with
Bregs (Pearson’s r = 0.396, p = 0.019).

Figure 3. A. Percentages of CD8+ T cells and B. CD8+ Tregs in all patients with COVID-19 and healthy
controls. C. Percentages of CD8+ Tregs in the mild, moderate, and severe group in patients with COVID-19.

893

UÇARYILMAZ et al. / Turk J Med Sci
Table 2. Laboratory findings of the COVID-19 patients.

Normal
range
Hematological parameters
White blood cell count, ×109/L

3.5–10.5

Neutrophil count, ×109/L

1.7–7

Lymphocyte count, ×109/L

0.9–2.9

Neutrophil-to-lymphocyte ratio
Platelet count, ×109/L

150–450

All
patients
(n = 50)

Study groups
Mild
(n = 14)

Moderate
(n = 22)

Severe
(n = 14)

p-value

6.0 ± 2.2
3.6
(0.5–10.9)
1.3 ± 0.6
2.8
(0.5–17)
193.5
(100–727)

5.2 ± 2.1
3
(0.5–7.5)a
1.4 ± 0.9
1.9
(0.5–12.5)
180.5
(126–430)

6.0 ± 2.2
3.1
(1.3–11)
1.5 ± 0.6a
1.9
(0.6–15.6)a
200.5
(100–727)

6.8 ± 2.4
4.5
(1.9–9.5)b
1.0 ± 0.3b
4.1
(1.6–17)b
189
(119–369)

0.1791

11.2
(10–15)
26.6
(22.4–42)
0.99
(0.86–1.5)
371.5
(98–1560)
419.2 ± 172.6

11
(10.2–13.3)a
26.1
(22.4–35.4)
1
(0.89–1.17)
213
(98–499)a
310.8 ± 59.7a

11
(10–14.4)a
25.6
(22.9–33)
0.95
(0.86–1.22)a
348
(100–1130)a
404.8 ± 121.4b

12.7
(10.7–15)b
27.1
(23.2–42)
1.11
(0.97–1.5)b
531
(310–1560)b
599.6 ± 217.4b

24.5
(8–192)
28
(13–148)
3.6 ± 0.4
0.5 ± 0.2
30.5
(13–120)
0.82
(0.58–4.83)
85
(28–584)
276.2 ± 114.3
114.2
(2.7–842.2)
9.86
(1.3–462)
0.05
(0.05–1.25)
2.9
(2.2–12)

18.5
(8–58)
21.5
(14–38)a
25
(14–120)
0.8
(0.6–4.8)
92.5
(28–211)
196.1 ± 46.3a
74.9
(2.7–408)a
4.9
(1.6–55.5)a
0.05
(0.05–1.25)a
2.8
(2.3–5.3)a

22.5
(9–192)
26
(13–148)a
3.7 ± 0.4
0.4 ± 0.2
32
(13–59)
0.8
(0.6–1.2)
57
(34–370)a
256.7 ± 66.3b
99.6
(6.1–584.7)a
8.4
(1.3–156)a
0.05
(0.05–0.20)a
2.4
(2.2–9.5)a

34.5
(11–64)
35
(18–91)b
3.5 ± 0.4
0.6 ± 0.2
33
(22–98)
0.9
(0.7–1.8)
154
(48–584)b
386.7 ± 138.9c
230.7
(21.2–842.2)b
119.3
(11.6–462)b
0.1
(0.05–0.64)b
5.1
(2.3–12)b

0.0432
0.0051
0.0152
0.2782

Coagulation parameters
Prothrombin time, seconds

10–14

Activated partial thromboplastin time,
21–36
seconds
Prothrombin-INR

0.8–1.3

D-dimer, ng/mL

0–500

Fibrinogen, mg/dL
200–400
Biochemical parameters and acute phase reactants
Alanine aminotransferase, U/L

0–50

Aspartate aminotransferase,U/L

0–50

Albumin, g/dL
Total bilirubin, mg/dL

3.5–5.2
0.22–1.4

Urea, mg/dL

17–43

Creatinine, mg/dL

0.67–1.2

Creatinine phosphokinase

34–171

Lactate dehydrogenase, U/L

126–222

Ferritin, ng/mL

23.9–336.2

C-reactive protein, mg/L

0–8

Procalcitonin, ng/mL

0–0.5

Troponin I, ng/L

0–17.5

Data were presented as mean ± standard deviation or median (min-max), as appropriate.
Different small superscript in each row denote that statistically significant between groups after pairwise comparisons.
1
Welch F test followed by Games-Howell posthoc test
2
Kruskal–Wallis test followed by Dunn posthoc test with Bonferroni correction.
3
Independent samples t-test.
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0.0102
0.3442
0.0032
0.0012
0.0021
0.1852
0.0142
0.2293
0.0833
0.2222
0.1262
0.0192
0.0011
0.0102
0.0012
0.0122
0.0152
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Table 3. The regulatory T Cells and B Cell subsets of the COVID-19 patients and healthy controls.

Control
(n = 50)

Study groups
All patients
p value Mild
Moderate
(n = 50)
(n = 14)
(n = 22)

CD3+ Total T (%)

71.4 ± 8.1

68.0 ± 10.3

0.0881

73
70.9
(47.6–78.6) (48–85.3)

64.6
0.0553
(36.9–81.1)

CD3+CD4+Th (%)

40.7 ± 7.9

40.0 ± 8.8

0.7261

40.2 ± 8.8

41.3 ± 9.0

37.9 ± 9.0

0.5374

CD3 CD8 Tc (%)

26.3 ± 9.2

21.3 ± 7.2

0.004

22.9 ± 7.2

21.5 ± 7.7

19.4 ± 6.2

0.4264

CD4/CD8 ratio

1.6
(0.5–5.4)

1.7
(0.9–8.7)

0.0992

1.7
(0.9–4.1)

1.9
(0.9–8.7)

1.8
(1.1–3.9)

0.7153

5.2
(1.6–15)

6.4
(1.3–10.9)

0.2022

6.1 ± 2.0

6.6 ± 1.6

6.4 ± 2.5

0.7584

I: CD3+CD4+CD45RA+Foxp3low
(RestingTregs=rTregs)

1.2 ± 0.8

1.3 ± 1.0

0.9221

1.7 ± 1.4

1.1 ± 0.8

1.1 ± 0.5

0.2905

II: CD3+CD4+CD45RA-Foxp3high
(ActivatedTregs=aTregs)

1.5 ± 1.7

1.7 ± 1.3

0.1341

1.6
(0.5–3.6)

1.8
(0.2–4.7)

1.2
(0.3–8.1)

0.6643

III: CD3+CD4+CD45RA-Foxp3low
(Nonsuppressive Tregs)

3.6
(1.1–11.2)

5
(2.3–13.6)

0.0202

3.9
(2.4–6.9)

5.5
(2.6–8.5)

5.2
(2.3–13.6)

0.1733

0.3
(0–1.5)

0.4
(0–4.2)

0.0012

0.3
(0–1.4)a

0.4
(0.2–2.2)a

0.9
(0.2–4.2)b

0.0053

10.3 ± 4.3

10.1 ± 5.6

0.8171

7.9 ± 3.2

11.5 ± 7.1

10.0 ± 4.4

0.1664

CD19+CD38highCD24high
(Bregs)

3.6 ± 2.2

5.2 ± 2.8

0.0051

6.3 ± 2.7

4.8 ± 3.0

4.6 ± 2.2

0.2084

CD19+CD38highCD24(Plasmablasts)

0.3
(0.1–8.4)

2.7
(0–10.4)

0.0011

3.2 ± 2.1

3.2 ± 2.2

2.9 ± 2.6

0.9134

CD19+CD38intCD24int
(Mature naive B cells)

48.6
(14.7–82.8)

54.6
0.0282
(19.9–71.7)

51.9 ± 11.4

56.1 ± 10.9

50.7 ± 15.5

0.3934

CD19+CD38-CD24+
(Primarily memory B cells)

34.8
(6.3–73.2)

21.5
(8.2–55.8)

0.0012

21.9
(9.9–55.8)

19.8
(8.2–46.8)

23.6
0.5043
(12.6–55.4)

CD19+CD38-CD24(New memory B cells)

5.2
(1.3–11.3)

4.5
(1.7–16.7)

0.2472

5.1
(2.2–11.3)

3.5
(1.7–9.5)

4.9
(1.7–16.7)

Severe
(n = 14)

p-value

Lymphocyte gate

+

+

1

CD3+CD4+Th gate (%)
CD3+CD4+CD25+Foxp3+(Tregs)

CD3+CD8+Tc gate (%)
CD3+CD8+CD25+Foxp3+
Lymphocyte gate (%)
CD19+ B cells
CD19 B gate (%)
+

0.2833

Data were presented as mean ± standard deviation or median (min-max), as appropriate.
Different small superscript in each row denote that statistically significant between groups after pairwise comparisons.
1
Independent samples t-test.
2
Mann–Whitney U test.
3
One-way ANOVA followed by Tukey HSD posthoc test.
4
Kruskal–Wallis test followed by Dunn posthoc test with Bonferroni correction.
5
Welch F test followed by Games-Howell posthoc test.
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Figure 4. A. Percentages of CD19+ B cells, Bregs, plazmablasts, and new memory B cells
B. Mature naïve B cells and primarily memory B cells in all patients with COVID-19
and healthy controls.

Serum procalcitonin levels were positively correlated
with nonsuppressive Tregs (Spearman’s rho = 0.326,
p = 0.021) and were negatively correlated with Bregs
(Spearman’s rho = –0.394, p = 0.005) and plasmablasts
(Spearman’s rho = –0.323, p = 0.022).
Total CD3+ T cells were negatively correlated with
length of stay in the hospital (r = –0.286, p = 0.044) and age
(r = –0.235, p = 0.026). Bregs were negatively correlated
with age (r = –0.293, p = 0.005). We analyzed CD4+ Tregs,
CD8+ Tregs, and Bregs with each other about correlation
and found no correlation of these cell subtypes.
4. Discussion
The molecular mechanisms of Foxp3 expression and
the antigen-specific response of CD4+ and CD8+ Treg
cells in COVID-19 remain unclear. The host response
to viruses compromises multiple cell types that have a
regulatory function. To the best of our knowledge, this is
the first study in which all regulatory cells (CD4+ Tregs,
CD8+ Tregs, and Bregs) were evaluated simultaneously
in COVID-19 patients. We showed that CD8+ Treg cells
were increased in all cases, and it was higher in severe
cases than the moderate and mild cases. CD8+ Tregs
have been shown that immunosupressive effects by
various mechanisms including direct lysis of target cells
and secretion of immune suppressive cytokines [19]. In
contrast to nonspecific CD4+ Tregs, CD8+ Tregs are highly
suppressive and described to target only activated T cells
for regulation [20,21]. Thus, these results suggested that
complementary regulatory mechanisms in the immune
system may be affected during SARS-CoV-2 infections.
In the literature, Tregs have been described to limit
immune-mediated inflammation and the extent of tissue
damage during virus infection [22]. Chen et al. [9] found
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that the proportion of CD45RA+ Tregs was significantly
lower in patients with severe cases than in those with
moderate cases (0.5% vs. 1.1%). Another study reported
that Treg levels in COVID-19 patients were lower in
severe cases [23]. Vick et al. [24] reported that SARSCoV-2 caused a disruption in the transport of Tregs from
the circulation to the respiratory tract and also led to the
accumulation of Tregs in the circulation and lung damage.
However, opposite findings have also been reported that
Treg levels were increased in COVID-19 patients [25,26].
We also observed that nonsuppressive Tregs increased in
patients but no other Tregs subsets. The nonsuppressive
Tregs are capable of secreting a series of cytokines
including interleukin (IL)-2, interferon-γ, and IL-17, but
without inhibitory activity [27]. These results showed
that the presence of inflammatory and immunosupressive
responses in all COVID patients.
In previous studies, although the proportion of T,
B, and NK cells was in the normal range in severe and
nonsevere cases, decreased numbers of circulating T-cell
subsets as a part of lymphopenia have been reported in
COVID-19 [9,23,28,29]. We found that the percentage of
CD8+ T cells was reduced in all patients with COVID-19.
CD8+ T cells can kill virus-infected cells, and they play a
vital role in clearing SARS-CoVs from infected cells and
induce immune injury [8]. Several potential mechanisms
have been defined, including immune complexes triggered
by viral infection, direct infection, promotion of growth
inhibition, and apoptosis of these cells. These findings
suggested that homeostasis among the T-cell subsets was
disrupted in patients with COVID-19.
We detected that the percentages of regulatory B cells,
plasmablasts, and mature naive B cells were increased
in patients. In addition, primarily memory B cells were
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decreased in patients. To our knowledge, this is the
first study evaluating regulatory B cells of patients with
laboratory-confirmed SARS-CoV-2 infection. The effects
of B cells on the clearance of viral infections are limited.
Only a few studies have investigated the role of Bregs in
infections of HIV and hepatitis B virus (HBV) [12–14].
The role of Bregs in viral infections is primarily through
IL-10-mediated immunological effects. A previous
study reported the B-cell-mediated regulation of T-cell
function in HIV infection via suppressing anti-HIV
effector CD8+ T cells [14]. Jiao et al. [12] found that Bregs
frequency correlated negatively with CD4 count, and
they determined that Breg phenotypes in HIV-infected
patients were CD19+CD24hiCD38hi. The level of IL10 was
also significantly higher in this population than the other
B-cell subsets [12]. We also identified Bregs according to
the CD19+CD24hiCD38hi population and demonstrated an
increase in this population in patients. These observations
may be explained by differences in infected individuals’
immune systems and by the effects of SARS-CoV-2 on
B-cell subsets.
Consistent with previous reports [5,6], similar
clinical features in patients with COVID-19 were noted
in the present study. The average age and the number of
comorbidities of patients in the severe group, including
hypertension and diabetes, were higher than in the
nonsevere groups. Although the female patient ratio was
higher (54.0%) and lymphopenia (≤ 1500) was detected in
68.0% of all patients, there was no relationship between
these parameters and disease severity.

In conclusion, the results presented here demonstrated
CD8+ Treg cells and Bregs were altered in COVID-19
patients. A better understanding of the immunoregulatory
mechanisms may assist in the elucidation of associated
factors in the progression of patients infected with
COVID-19.
Limitations of study
The current study has a number of limitations. One of
them the sample size was small, as we excluded patients
who received any treatment for COVID-19. We performed
flow cytometric analysis only in 24 h at admission. The
other one is there were only 3 exitus patients, and therefore
we could not perform a mortality analysis.
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